7498 Results (Page 244 of 300)
Pharmaceuticals Markets Research Reports
Romania Breast Cancer Therapeutics Market Analysis
Due to the rising prevalence of breast cancer and acceptance of new targeted therapeutics, the Romania breast cancer therapeutics market is expected to witness growth from $53 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the year 2022-2030. The market is segmented by therapy, by cancer type, and by distribution channel. Antibiotice, Bristol-Myers Squibb, and Eli Lilly are the key competitors in the Romania breast cancer therapeutics market.
Netherlands Breast Cancer Therapeutics Market Analysis
The Netherlands breast cancer therapeutics market is expected to witness growth from $47 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the year 2022-2030 due to market growth drivers like increasing awareness about the breast cancer therapies and rising research and development activities in the Netherlands. The market is segmented by therapy, by cancer type, and by distribution channel. Rousselot, Oncogenex, and Apthera are some of the major players in the Netherlands breast cancer therapeutics market.
US Dermatology Drugs Market Analysis
By 2030, it is anticipated that the US Dermatology drugs market will reach a value of $14 Bn from $7.14 Bn in 2022, growing at a CAGR of 8.8% during 2022-2030. The dermatology drug market in the US is dominated by a few large pharmaceutical companies such as Amgen Inc., Eli Lilly, and AbbVie. The dermatology drug market in the US is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel. The major factors affecting the US dermatology drugs market are the increasing disease burden of non-communicable diseases like cancer and the lack of healthcare facilities for cancer treatment in most areas of the US.
Singapore Breast Cancer Therapeutics Market Analysis
The Singapore breast cancer therapeutics market is growing from $22 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the forecasted year 2022-2030 due to the changing lifestyle choices leading to obesity and rising incidence of breast cancer in Singapore. The market is segmented by therapy, by cancer type, and by distribution channel. Beacons Pharmaceuticals, Bristol-Myers Squibb Co., and Eli Lilly and Co. are the leading companies in the Singapore breast cancer therapeutics market.
Malaysia Breast Cancer Therapeutics Market Analysis
The Malaysia breast cancer therapeutics market is expected to grow from $29 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the year 2022-2030. The rising incomes and continuously improving healthcare infrastructure in Malaysia are major market drivers in the breast cancer therapeutics market. The market is segmented by therapy, by cancer type, and by distribution channel. Royce Pharma Manufacturing, Johnson & Johnson Private Limited, and Cipla are some of the leading companies in the Malaysia breast cancer therapeutics market.
Japan Women's Health Market Analysis
The Japan Women’s Health Market is projected to grow from $2.483 Bn in 2022 to $3.753 Bn by 2030, registering a CAGR of 5.30% during the forecast period of 2022 - 2030. Women in Japan are becoming more aware of the importance of maintaining their health and are seeking out more information and products related to their well-being. Companies such as Pfizer, Astellas, and Takeda are major players in the Japan women's health market, producing drugs and supplements for conditions such as osteoporosis and menopause.
Brazil Women's Health Market Analysis
The Brazil Women’s Health Market is projected to grow from $0.999 Bn in 2022 to $1.568 Bn by 2030, registering a CAGR of 5.80% during the forecast period of 2022 - 2030. The Brazilian Government's initiative for Universal Health coverage and the increasing public and private sector participation in the healthcare market will also drive the growth of the women's health market in the country. There are some of the major companies operating in the Brazil women's health market include pharmaceutical giants such as Pfizer and Roche, Bayer.
UAE Breast Cancer Therapeutics Market Analysis
The UAE breast cancer therapeutics market is expected to witness growth from $91 Mn in 2022 to $258 Mn in 2030 with a CAGR of 13.9% for the year 2022-2030. Market drivers for the UAE breast cancer therapeutics market are the rising prevalence of breast cancer and the development of new therapies for its treatment. The market is segmented by therapy, by cancer type, and by distribution channel. Gulf Pharmaceutical Industries JULPHAR, Pfizer, and Roche are some of the major companies in the market.
Indonesia Breast Cancer Therapeutics Market Analysis
The Indonesia breast cancer therapeutics market is expected to grow from $109 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the year 2022-2030. The breast cancer therapeutics market growth drivers in Indonesia are the growing prevalence of breast cancer and increasing research and development activities in breast cancer therapeutics. The market is segmented by therapy, by cancer type, and by distribution channel. Sanbe Pharma, Biocon, and Merck & Co. Inc. are leading companies in Indonesia's breast cancer therapeutics market.
Spain Oncology Drugs Market Analysis
By 2030, it is anticipated that the Spain oncology drugs market will reach a value of $8.5 Bn from $3.8 Bn in 2022, growing at a CAGR of 10.6% during 2022-2030. The oncology drug market in Spain is dominated by a few large pharmaceutical companies such as Highlight Therapeutics, Peptomyc, and Oryzon Genomics. The oncology market in Spain is segmented by different therapeutic areas, into breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. The market is also segmented based on treatment type, such as surgery, radiation therapy, chemotherapy, and targeted therapy.
Italy Oncology Drugs Market Analysis
By 2030, it is anticipated that the Italy oncology drugs market will reach a value of $10.9 Bn from $4.7 Bn in 2022, growing at a CAGR of 11.1% during 2022-2030. The oncology drug market in Italy is dominated by a few large pharmaceutical companies such as Sanofi, Novartis, Roche, and Pfizer. The oncology market in Italy is segmented into different therapeutic areas, such as breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. The market is also segmented based on treatment type, such as surgery, radiation therapy, chemotherapy, and targeted therapy.
US Women's Health Market Analysis
The US Women’s Health Market is projected to grow from $16.775 Bn in 2022 to $20.922 Bn by 2030, registering a CAGR of 2.80% during the forecast period of 2022 - 2030. As more women become aware of the importance of taking care of their health and the availability of new and innovative products and technologies, the demand for women's health products and services is increasing. Some key players in the US Women's Health market include Pfizer, Merck, AbbVie, Allergan, GlaxoSmithKline, Lilly, Novo Nordisk, Roche, Sanofi, Teva, Mylan, and Actavis.
China Women's Health Market Analysis
The China Women’s Health Market is projected to grow from $3.211 Bn in 2022 to $5.234 Bn by 2030, registering a CAGR of 6.30% during the forecast period of 2022 - 2030. The increasing number of working women in China is driving the women's health market as they have more disposable income and need for health care services. Some key players in the China Women's Health market include Peking Union Medical College Hospital and China Women's Health Group.
Canada Women's Health Market Analysis
The Canada Women’s Health Market is projected to grow from $3.195 Bn in 2022 to $4.649 Bn by 2030, registering a CAGR of 4.80% during the forecast period of 2022 - 2030. As more women become aware of the importance of taking care of their health and the availability of new and innovative products and technologies, the demand for women's health products and services is increasing. Some key players in the Canada Women's Health market include Shoppers Drug Mart, Rexall, London Drugs, Well.ca, Jean Coutu, Pharmasave, Uniprix, Lawtons Drugs, Proxim, and IDA Pharmacy.
Brazil ADHD (Attention Deficit Hyperactivity Disorder) Drugs Market Analysis
The Brazil ADHD (Attention Deficit Hyperactivity Disorder) Drugs Market is projected to grow from $0.739 Bn in 2022 to $1.109 Bn by 2030, registering a CAGR of 5.20% during the forecast period of 2022 - 2030. The Brazil government plays a significant role in the market through its reimbursement policies and regulations, which can affect the pricing and availability of drugs. Some of the major players in the Brazil ADHD drugs market include Shire (now part of Takeda), Novartis, and Janssen.
Australia Lung Cancer Drugs Market Analysis
The Australia Lung Cancer Drug Market is projected to grow from $115 Mn in 2022 to $242 Mn by 2030, registering a CAGR of 9.80% during the forecast period of 2022 – 2030. The incidence of lung cancer in Australia has been increasing in recent years, due in part to the high rates of smoking in the country. Some of the key players in the lung cancer drug market in Australia include AstraZeneca, Roche, Merck, Pfizer, and Bristol-Myers Squibb.
UK Anti-Aging Drugs Market Analysis
This report presents a strategic analysis of the UK Anti-Aging Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UK Anti-Aging Drugs Market , offering unmatched value, accuracy, and expert insights.
US Breast Cancer Therapeutics Market Analysis
The US breast cancer therapeutics market size is projected to grow to $ 17.48 Bn by 2030 from $7.64 Bn in 2022, exhibiting a CAGR of 10.9% during the forecast period (2022-2030), according to the study conducted by Insights10. A lifetime diagnosis of invasive breast cancer is estimated to occur in 13% of women (1 in 8), and 3% (1 in 39) are prone to mortality, according to the American Cancer Society (US) Statistics 2020. Newer interventions in the competitive landscape are estimated to reach $4.6 Bn in revenues from major players like AstraZeneca, and Daiichii Sankyo thanks to the sizeable market demands.
Japan Breast Cancer Therapeutics Market Analysis
The Japan breast cancer therapeutics market is expected to witness growth from $1.13 Bn in 2022 with a CAGR of 13.4% for the forecasted year 2022-2030 to $3.09 Bn in 2030 due to growth drivers like the increasing incidence of breast cancer and awareness programs in Japan. The breast cancer therapeutics market is segmented by therapy, by cancer type, and by distribution channel. Major players in Japan breast cancer therapeutics market include Takeda Pharmaceutical Co. Ltd., Eisai Co., Ltd, AstraZeneca PLC.
India Breast Cancer Therapeutics Market Analysis
The India breast cancer therapeutics market is witnessing a boost from $331 Mn in 2022 to $1,078 Mn in 2030 with a CAGR of 15.9% for the period 2022-2030 mainly due to increased incidence of breast cancer and novel treatment advances. The market is segmented by therapy, by cancer type and by distribution channel. Key players like Sun Pharmaceutical Industries, AbbVie Inc., and Amgen Inc. are leading companies in the breast cancer therapeutics market.
China Breast Cancer Therapeutics Market Analysis
With rising incidences of breast cancer and new technological advancements in breast cancer therapeutics, the China breast cancer therapeutics market is projected to expand from $1.46 Bn in 2022 with a CAGR of 14.4% for the year 2022-2030 to $4.29 Bn in 2030. The China breast cancer market is segmented by therapy, cancer type, and by distribution channel. Shenzhen Main Luck Pharmaceuticals Inc., Bristol-Myers Squibb Co., Eli Lilly, and Co. are some of the key players in the market.
Canada Breast Cancer Therapeutics Market Analysis
The Canada breast cancer therapeutics market size is valued at $1.45 Bn in 2022 and is estimated to expand at a compound annual growth rate of 12.9% from 2022 to 2030 and will reach $3.84 Bn in 2030 and this rise is attributed to the novel therapies for curing breast cancer and increasing research and development activities in Canada. The market is segmented by therapy, by cancer type and by distribution channel. Some of the leading companies in the market are Johnson & Johnson Services Inc., Pfizer Inc., AbbVie Inc., etc.
UK Oncology Drugs Market Analysis
By 2030, it is anticipated that the UK oncology drugs market will reach a value of $10.6 Bn from $5.1 Bn in 2022, growing at a CAGR of 9.6% during 2022-2030. The companies operating in the oncology drug in the UK market are Immunocore, Adaptimmune, and Oxford BioMedica. The UK oncology drugs market is segmented on the basis of therapy modality and types of cancer. The market is influenced by the National Health Service (NHS) which is responsible for the majority of cancer drug spending in the UK.
Australia Oncology Drugs Market Analysis
By 2030, it is anticipated that the Australia oncology drugs market will reach a value of $6.3 Bn from $2.36 Bn in 2022, growing at a CAGR of 13.1% during 2022-2030. The companies operating in the oncology drug in Australia market are Bristol Myers Squibb, Aucentra Therapeutics, and Natco Pharma. The Australia oncology drugs market is segmented on the basis of therapy modality and types of cancer. Factors such as increased awareness about cancer and its treatments and taxation policies by the government are some of the major drivers of growth in the Australian oncology drug market.
China ADHD (Attention Deficit Hyperactivity Disorder) Drugs Market Analysis
The China ADHD (Attention Deficit Hyperactivity Disorder) Drugs Market is projected to grow from $2.376 Bn in 2022 to $3.702 Bn by 2030, registering a CAGR of 5.70% during the forecast period of 2022 - 2030. The number of individuals diagnosed with ADHD is on the rise in China, leading to a higher demand for ADHD medications. Some of the key players in the China ADHD (Attention Deficit Hyperactivity Disorder) Drugs Market include Novartis, Pfizer, Shire (now part of Takeda), CSPC Pharmaceutical Group, Lanzhou Institute of Biological Products, Huadong Medicine, Hainan Zhongxin Pharmaceutical, Jiangsu Hengrui Medicine, Hunan Erkang Pharmaceutical, Tiantai Pharmaceutical.
